US2021252071A1PendingUtilityA1

Method for cartilage repair and pre-osteoarthritis treatment

35
Assignee: UNIV LOUISIANA STATEPriority: Feb 14, 2020Filed: Feb 14, 2020Published: Aug 19, 2021
Est. expiryFeb 14, 2040(~13.5 yrs left)· nominal 20-yr term from priority
Inventors:Yufeng Dong
A61K 35/28A61K 9/0019A61K 38/177A61P 19/02
35
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions comprising an isolated in vitro pre-conditioned population of placenta derived mesenchymal stem cells (PMSCs), wherein the PMSCs promote de novo regeneration of cartilage when the PMSCs are administered to a subject. A method of treating one of osteoarthritis, cartilage damage or loss, and pre-osteoarthritis in a patient comprising administering to the patient a pharmaceutical composition comprising an isolated in vitro pre-conditioned population of placenta derived mesenchymal stem cells (PMSCs), wherein the in vitro pre-conditioning comprises providing a population of mesenchymal stem cells from a placenta, and culturing the population of mesenchymal stem cells in a medium comprising soluble Notch ligand Jagged1 (JAG1); and a pharmaceutically acceptable carrier. A pharmaceutical composition comprising placenta derived mesenchymal stem cells (PMSCs), Notch ligand Jagged1 (JAG1), and a pharmaceutically acceptable carrier.

Claims

exact text as granted — not AI-modified
Wherefore, I claim: 
     
         1 . A composition comprising:
 an isolated in vitro pre-conditioned population of placenta derived mesenchymal stem cells (PMSCs),   wherein the PMSCs promote de novo regeneration of cartilage when the PMSCs are administered to a subject.   
     
     
         2 . The composition of  claim 1 , wherein the in vitro pre-conditioning comprises providing a population of mesenchymal stem cells from a placenta, and culturing the population of mesenchymal stem cells in a medium comprising soluble Notch ligand Jagged1 (JAG1). 
     
     
         3 . The composition of  claim 2  wherein the JAG1 is in a concentration of between 5.0 μg/ml and 15 μg/ml. 
     
     
         4 . The composition of  claim 2  wherein the JAG1 is in a concentration of substantially 10 μg/ml. 
     
     
         5 . The composition of  claim 1  wherein the PMSCs are harvested from a villous tissue of the placenta. 
     
     
         6 . A method of treating one of osteoarthritis, cartilage damage or loss, and pre-osteoarthritis in a patient comprising:
 administering to the patient a pharmaceutical composition comprising
 an isolated in vitro pre-conditioned population of placenta derived mesenchymal stem cells (PMSCs), wherein the in vitro pre-conditioning comprises providing a population of mesenchymal stem cells from a placenta, and culturing the population of mesenchymal stem cells in a medium comprising soluble Notch ligand Jagged1 (JAG1); and 
 a pharmaceutically acceptable carrier. 
   
     
     
         7 . The method of  claim 6  wherein the pharmaceutical composition is injected into a joint of the patient. 
     
     
         8 . The method of  claim 7  wherein the joint is a knee. 
     
     
         9 . The method of  claim 6  wherein the pharmaceutical composition contains between 0.1 million and 300 million PMSCs. 
     
     
         10 . The method of  claim 6  wherein the pharmaceutical composition contains between 0.2 million and 30 million PMSCs. 
     
     
         11 . The method of  claim 6  wherein the pharmaceutical composition contains between 0.5 million and 3 million PMSCs. 
     
     
         12 . The method of  claim 6  further comprising making no more than one injection of the pharmaceutical composition into the patient a week. 
     
     
         13 . The method of  claim 12  further comprising making one injection of the pharmaceutical composition into the patient a week for four weeks. 
     
     
         14 . The method of  claim 6  wherein the pharmaceutical composition contains JAG1. 
     
     
         15 . The method of  claim 14  wherein JAG1 is in a concentration of between 5.0 μg/ml and 15 μg/ml. 
     
     
         16 . The method of  claim 14  wherein the JAG1 is in a concentration of substantially 10 μg/ml. 
     
     
         17 . The method of  claim 6  wherein the PMSCs are harvested from a villous tissue of the placenta. 
     
     
         18 . A pharmaceutical composition comprising:
 placenta derived mesenchymal stem cells (PMSCs),   Notch ligand Jagged1 (JAG1); and   a pharmaceutically acceptable carrier.   
     
     
         19 . The pharmaceutical composition of  claim 18  wherein the wherein the PMSCs are harvested from a villous tissue of a human placenta. 
     
     
         20 . The pharmaceutical composition of  claim 19  wherein the JAG1 is in a concentration of between 8.0 μg/ml and 12.0 μg/ml.

Join the waitlist — get patent alerts

Track US2021252071A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.